

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

HCC1806

RRID:CVCL_1258

Type: Cell Line

Proper Citation

RRID:CVCL_1258

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1258

Proper Citation: RRID:CVCL_1258

Description: Cell line HCC1806 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast acantholytic squamous cell carcinoma

Defining Citation: [PMID:9288768](#), [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12353263](#), [PMID:12800145](#), [PMID:19582160](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20679594](#), [PMID:21603256](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25892236](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30787054](#), [PMID:30835260](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:40300663](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: African American., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1806

Synonyms: Hcc1806, HCC-1806, Hamon Cancer Center 1806

Cross References: BTO:BTO_0006395, CLO:CLO_0003644, EFO:EFO_0005373, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2335, BioGRID_ORCS_Cell_line:662, BioSample:SAMN03472709, BioSample:SAMN10988428, cancercellines:CVCL_1258, Cell_Model_Passport:SIDM00875, ChEMBL-Cells:ChEMBL3308135, ChEMBL-Targets:ChEMBL1075457, CLS:300467, Cosmic:687479, Cosmic:904367, Cosmic:907047, Cosmic:1047705, Cosmic:1287888, Cosmic:1460234, Cosmic:1603206, Cosmic:1935008, Cosmic-CLP:907047, DepMap:ACH-000624, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10717-109I6, GDSC:907047, GEO:GSM217576, GEO:GSM219878, GEO:GSM344339, GEO:GSM344389, GEO:GSM350528, GEO:GSM378147, GEO:GSM783942, GEO:GSM844546, GEO:GSM844547, GEO:GSM847325, GEO:GSM847482, GEO:GSM887044, GEO:GSM888114, GEO:GSM1053713, GEO:GSM1172869, GEO:GSM1172960, GEO:GSM1374504, GEO:GSM1374505, GEO:GSM1669850, IARC_TP53:10273, KCB:KCB_2014032YJ, LiGeA:CCLE_250, LINCS_HMS:50211, LINCS_LDP:LCL-1960, PharmacDB:HCC1806_483_2019, PRIDE:PXD008222, PRIDE:PXD030304, Progenetix:CVCL_1258, PubChem_Cell_line:CVCL_1258, SLKBase:3534, Ubigen:YC-C073, Wikidata:Q54881605

ID: CVCL_1258

Record Creation Time: 20220427T220318+0000

Record Last Update: 20260829T233629+0000

Ratings and Alerts

No rating or validation information has been found for HCC1806.

No alerts have been found for HCC1806.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 590 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Bai Y, et al. (2026) Epigenetic Regulation of Chromosomal Instability by EZH2 Methyltransferase. Cancer discovery, 16(1), 135.

Nandi D, et al. (2026) Spermine Oxidase Serves as a Key Functional Node in Microbial Dysbiosis-Induced Breast Carcinogenesis. Cancer research, 86(8), 1920.

Cruz A, et al. (2026) Targeting TNBC: core-shell polycationic polyurea dendrimers with inherent anticancer activity. FEBS open bio, 16(5), 944.

Wang Z, et al. (2026) RAD51 succinylation regulates homologous recombination and contributes to the chemosensitivity in cancer. *Molecular cell*, 86(4), 585.

Li Z, et al. (2026) Exploration of precise classification and therapeutic targets of breast cancer based on genes related to neuro-cancer crosstalk. *Translational oncology*, 64, 102647.

MacLean MR, et al. (2026) Selective inhibition of ALDH1A3 impedes breast cancer growth and metastasis by blocking ALDH1A3-driven transcriptional programs. *iScience*, 29(3), 114863.

Hachey JS, et al. (2026) Exploring the 89Zr/177Lu Theranostic Pairing with an Extracellular Matrix-Targeted Radiopharmaceutical against Triple-Negative Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(7), 1337.

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Rampa DR, et al. (2026) Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(8), 1454.

Luo L, et al. (2026) CDK2 inhibitor BLU-222 synergizes with CDK4/6 inhibitors in drug resistant breast cancers through p21/p27 induction. *Nature communications*, 17(1), 619.

Lin W, et al. (2026) FAM135B Deficiency Inhibits Cytotoxic T-cell Activity in Triple-Negative Breast Cancer by Blocking the IFI16-Dependent STING Pathway. *Cancer immunology research*, 14(2), 335.

Xu Y, et al. (2026) Comprehensive single-cell metabolic profiling identifies targets to sensitize triple-negative breast cancer to chemo-immunotherapy. *Cell reports. Medicine*, 7(3), 102659.

Sun GS, et al. (2026) AK5 suppresses breast cancer progression and modulates anti-PD-L1 efficacy via the miR-182-5p/PD-L1 axis. *iScience*, 29(4), 115260.

Miao J, et al. (2025) KIF18A promotes chromosome congression in cooperation with CENP-E downstream of CENP-C. *Cell reports*, 44(11), 116515.

Abelman RO, et al. (2025) TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*.

Suresh S, et al. (2025) PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. *Scientific reports*, 15(1), 36766.

Smoak CN, et al. (2025) ZYS-1 is not an ADAR1 inhibitor. *RNA (New York, N.Y.)*, 31(12), 1703.

Jeon JH, et al. (2025) Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer.

Cancer & metabolism, 13(1), 42.

Mahajan M, et al. (2025) The Discovery and Characterization of HBS-101, a Novel Inhibitor of Midkine, as a Therapeutic Agent for the Treatment of Triple-Negative Breast Cancer. *Molecular cancer therapeutics*, 24(9), 1308.

Zhang Y, et al. (2025) Immune targeting of triple-negative breast cancer through a clinically actionable STING agonist-CAR T cell platform. *Cell reports. Medicine*, 6(7), 102198.